Description
Prostate cancer is the third most frequent cancer in men worldwide, with a notable increase in prevalence over the last two decades. The PSA is the only well-established protein biomarker for prostate cancer diagnosis, staging, and sur-veillance. It frequently leads to inaccurate diagnosis and overtreatment since it is an organ-specific biomarker rather than a tumour-specific biomarker. As a result, one of the primary goals of prostate cancer proteome research is to iden-tify novel biomarkers that can be used with or instead of PSA, particularly in non-invasive blood samples. Thousands of peptides or assays were detected in blood samples from patients with low to high-grade prostate cancer and healthy individuals, allowing data processing of sequential window acquisition of all theoretical mass spectra (SWATH-MS). By assisting in the detection of prostate cancer biomarkers in blood samples, this useful resource will improve our un-derstanding of the role of proteomics in prostate cancer diagnosis and risk assessment.
Date made available | 2021 |
---|---|
Publisher | PRoteomics IDEntifications Database |
Date of data production | 20 Dec 2021 |
Keywords
- Prostate cancer
- spectral library
- blood proteomics
- protein
- peptide
- mass spectrometry
- SWATH-MS
Equipment
-
Biological Mass Spectrometry (BioMS) Facility
Knight, D. (Platform Lead), Warwood, S. (Senior Technical Specialist), Selley, J. (Technical Specialist), Taylor, G. (Technical Specialist), Fullwood, P. (Technical Specialist), Keevill, E.-J. (Senior Technician) & Allsey, J. (Technician)
FBMH Platform Sciences, Enabling Technologies & InfrastructureFacility/equipment: Facility